Pfizer Inc. discontinues development of danuglipron, a weight management pill, after a trial participant experiences liver injury. The company vows to continue research in obesity ...
Pfizer stops the development of its weight loss pill, danuglipron, after a trial participant suffered liver injury. The company vows to continue its research in obesity treatments,...
Pfizer Inc. stops development of weight loss pill danuglipron after a trial participant suffers liver injury. The company pledges to continue research into obesity treatments, high...
Pfizer Inc. has discontinued the development of its weight management pill, danuglipron, after a trial participant experienced liver injury. The company remains focused on advancin...
The US Attorney's office is investigating claims that Pfizer delayed announcing its COVID-19 vaccine success until after the 2020 election. Former employee Phil Dormitzer's alleged...
Pfizer projects its 2025 revenue to reach up to $64 billion, with steady COVID-19 product sales and anticipated operational growth of 10% to 18% year-over-year.
